Abstract：
UNASSIGNED: To assess ocular, visual, and anatomical outcomes following the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN®) and incisional intraocular pressure (IOP)-lowering surgery in diabetic macular edema.
UNASSIGNED: From a 36-month, phase 4, open-label, observational study (N = 202 eyes, 159 patients), 8 eyes (7 patients) required IOP-lowering surgery post-FAc; eyes were segregated by FAc-induced (n = 5, 2.47%) versus neovascular glaucoma (NVG)-related (n = 3, 1.49%) IOP elevations and assessed for IOP, best corrected visual acuity (BCVA), central subfield thickness (CST), and cup-to-disc ratio (c/d).
UNASSIGNED: Changes at 36 months were +5.4 letters BCVA (P > 0.05) and +0.09 c/d (P = 0.0217); IOP and CST were unchanged. FAc-induced-group eyes required fewer IOP-lowering medications than NVG-group eyes (2.0 versus 4.0; P < 0.01) but for longer duration (15.2 versus 2.6 months; P < 0.001).
UNASSIGNED: Post-FAc IOP-lowering surgery, regardless of cause, largely did not affect the outcomes measured; these procedures, then, may not meaningfully threaten positive outcomes. [Ophthalmic Surg Lasers Imaging Retina 2024;55:22-29.].
UNASSIGNED: From a 36-month, phase 4, open-label, observational study (N = 202 eyes, 159 patients), 8 eyes (7 patients) required IOP-lowering surgery post-FAc; eyes were segregated by FAc-induced (n = 5, 2.47%) versus neovascular glaucoma (NVG)-related (n = 3, 1.49%) IOP elevations and assessed for IOP, best corrected visual acuity (BCVA), central subfield thickness (CST), and cup-to-disc ratio (c/d).
UNASSIGNED: Changes at 36 months were +5.4 letters BCVA (P > 0.05) and +0.09 c/d (P = 0.0217); IOP and CST were unchanged. FAc-induced-group eyes required fewer IOP-lowering medications than NVG-group eyes (2.0 versus 4.0; P < 0.01) but for longer duration (15.2 versus 2.6 months; P < 0.001).
UNASSIGNED: Post-FAc IOP-lowering surgery, regardless of cause, largely did not affect the outcomes measured; these procedures, then, may not meaningfully threaten positive outcomes. [Ophthalmic Surg Lasers Imaging Retina 2024;55:22-29.].
摘要：
■为了评估眼睛，视觉，糖尿病性黄斑水肿患者接受0.19mg醋酸氟轻松(FAc)玻璃体内植入(ILUVIEW®)和降低切口眼压(IOP)手术后的解剖学结果。
■从36个月开始，阶段4，开放标签，观察性研究(N=202眼，159名患者），8只眼(7例患者)在FAc术后需要降低眼压手术;通过FAc诱导(n=5,2.47%)与新生血管性青光眼(NVG)相关(n=3,1.49%)眼压升高和眼压评估,最佳矫正视力（BCVA），中心子场厚度（CST），和杯盘比（c/d）。
■36个月时的变化分别为5.4个字母BCVA（P>0.05）和0.09c/d（P=0.0217）；IOP和CST无变化。FAc诱导组眼睛比NVG组眼睛需要更少的降IOP药物（2.0对4.0;P<0.01），但持续时间更长（15.2对2.6个月;P<0.001）。
■FAc降低眼压手术后，不管什么原因,在很大程度上没有影响测量的结果；这些程序，然后,可能不会有意义地威胁积极的结果。[眼科手术激光成像视网膜2024；55：22-29。].
■从36个月开始，阶段4，开放标签，观察性研究(N=202眼，159名患者），8只眼(7例患者)在FAc术后需要降低眼压手术;通过FAc诱导(n=5,2.47%)与新生血管性青光眼(NVG)相关(n=3,1.49%)眼压升高和眼压评估,最佳矫正视力（BCVA），中心子场厚度（CST），和杯盘比（c/d）。
■36个月时的变化分别为5.4个字母BCVA（P>0.05）和0.09c/d（P=0.0217）；IOP和CST无变化。FAc诱导组眼睛比NVG组眼睛需要更少的降IOP药物（2.0对4.0;P<0.01），但持续时间更长（15.2对2.6个月;P<0.001）。
■FAc降低眼压手术后，不管什么原因,在很大程度上没有影响测量的结果；这些程序，然后,可能不会有意义地威胁积极的结果。[眼科手术激光成像视网膜2024；55：22-29。].
